Alvarez Alva Lucia, Maisonet Irma O, Ruiz Omar, Lumsden Rebecca S, Ferreira Ana Paula Evangelista, Avila Flores Esther M
Global Regulatory Affairs International, Pfizer Ltd, Bogotá, Colombia.
Global Regulatory Affairs International, Pfizer Ltd, San Juan, PR, United States.
Front Med (Lausanne). 2023 May 16;10:1102452. doi: 10.3389/fmed.2023.1102452. eCollection 2023.
The Latin America region comprises several countries that do not follow harmonized regulatory requirements for drug product (DP) marketing authorization applications (MAA), resulting in customized registration dossiers for each country. Here, we established a core dossier for multiple MAA in the Latin America region by examining the similarities between regulatory requirements and reconciling their potential discrepancies through discussions among all national regulatory representatives. The core dossier was used in the submission of a new small molecule, NME1, to nine markets. Assessment of the process included the time to submission; the timing, number, and complexity of questions received; and timing of final national regulatory agencies (NRA) evaluation decisions. The core dossier resulted in an accelerated submission timeline for most markets and earlier receipt of NRA queries from some markets, compared with projections. One round of queries of a low or medium complexity was received from all agencies. The receipt of final NRA evaluation decisions was also accelerated in most markets, compared with the best-case approval timeframes. The core dossier approach was also evaluated against the standard submission of a similar small molecule, NME2. In contrast to the core dossier submission of NME1, a second round of questions, and high-complexity questions were received from two markets for NME2. In conclusion, a core dossier has the potential to simplify the regulatory process for both reviewers and applicants in regions that do not share harmonized regulatory requirements, with a consequential acceleration of DP approvals.
拉丁美洲地区由几个国家组成,这些国家对药品上市许可申请(MAA)没有遵循统一的监管要求,导致每个国家都有定制的注册档案。在此,我们通过研究监管要求之间的相似性,并通过所有国家监管代表之间的讨论协调其潜在差异,为拉丁美洲地区的多个MAA建立了一个核心档案。该核心档案用于向九个市场提交一种新的小分子药物NME1。对该过程的评估包括提交时间;收到问题的时间、数量和复杂性;以及国家监管机构(NRA)最终评估决定的时间。与预期相比,核心档案使大多数市场的提交时间线加快,并且一些市场更早收到NRA的询问。所有机构都收到了一轮低或中等复杂性的询问。与最佳情况的批准时间框架相比,大多数市场收到NRA最终评估决定的时间也加快了。还将核心档案方法与一种类似小分子药物NME2的标准提交进行了评估。与NME1的核心档案提交不同,NME2从两个市场收到了第二轮问题以及高复杂性问题。总之,对于没有统一监管要求的地区,核心档案有可能简化审评人员和申请人的监管流程,从而加快药品批准。